Background
Evidence-based consensus guideline (SSO-ASTRO-ASCO) on surgical margins for BCS with whole-breast irradiation in stages I and II invasive breast cancer. Meta-analysis of 33 studies including 28,162 patients. Developed to define the minimum acceptable margin width for invasive breast cancer treated with BCS + RT and to reduce variability and unnecessary re-excision rates.
Interventions and follow up
Arm A: N/A — consensus guideline based on meta-analysi
Arm B: N/A
Primary endpoint: Ipsilateral breast tumor recurrence (IBTR) by margin statu
mFollow up: Variable across included studie
Arm B: N/A
Primary endpoint: Ipsilateral breast tumor recurrence (IBTR) by margin statu
mFollow up: Variable across included studie
Results
Positive margins (ink on tumor) vs negative: 2-fold increased IBTR risk (OR 2.44, P<.0001)
1 mm vs "no ink on tumor": No significant reduction in IBTR with wider negative margins
2 mm vs "no ink on tumor": No significant reduction in IBTR
Higher-risk subgroups (young patients, lobular, unfavorable biology): No evidence that wider margins reduce IBTR beyond "no ink on tumor"
1 mm vs "no ink on tumor": No significant reduction in IBTR with wider negative margins
2 mm vs "no ink on tumor": No significant reduction in IBTR
Higher-risk subgroups (young patients, lobular, unfavorable biology): No evidence that wider margins reduce IBTR beyond "no ink on tumor"
Adverse events
Main adverse events: Not applicable — guideline based on outcomes data, not a treatment trial. Inadequate margins (positive) are associated with higher re-excision rates and potential mastectomy.
Conclusions
For invasive breast cancer treated with BCS + whole breast RT with modern systemic therapy, "no ink on tumor" is the standard for an adequate margin. Routinely using wider margins (1, 2, or 3 mm) does not further reduce IBTR compared to no ink on tumor, even in high-risk subgroups. This single standard has the potential to substantially reduce unnecessary re-excision rates.
Key Limitations
Key Limitations: Meta-analysis of largely retrospective data. Wide variation in margin definitions, tumor biology, systemic treatment, and RT techniques across included studies. The guideline applies to invasive cancer treated with WBI + modern systemic therapy only — not applicable to: mastectomy patients, DCIS (see companion DCIS margins guideline), patients undergoing APBI, or patients without systemic therapy. Young age and biologic subtype are noted as potential modifiers but evidence was insufficient to define different margin thresholds.
Clinical Context
This guideline was published simultaneously with a companion DCIS margins guideline (Morrow et al, JCO 2016) and has been widely adopted. It represents a significant practice change from prior institutional standards requiring 1-2+ mm margins, and is expected to reduce mastectomy rates and improve cosmetic outcomes. For DCIS, the more conservative 2 mm threshold remains the standard because DCIS can extend beyond the visible lesion.
References